Efficacy and Safety of Tamsulosin for the Treatment of Non-neurogenic Voiding Dysfunction in Females: A 8-Week Prospective Study.
10.3346/jkms.2010.25.1.117
- Author:
Kyu Sung LEE
1
;
Deok Hyun HAN
;
Young Suk LEE
;
Myung Soo CHOO
;
Tag Keun YOO
;
Heung Jae PARK
;
Hana YOON
;
Hyeon JEONG
;
Sun Ju LEE
;
Hayoung KIM
;
Won Hee PARK
Author Information
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial ; Multicenter Study
- Keywords:
Urination Disorders;
Female;
Adrenergic alpha-Antagonists;
Outcomes Assessment
- MeSH:
Adrenergic alpha-Antagonists/adverse effects/pharmacokinetics/*therapeutic use;
Adult;
Aged;
Aged, 80 and over;
Female;
Humans;
Middle Aged;
Questionnaires;
Severity of Illness Index;
Sulfonamides/adverse effects/pharmacokinetics/*therapeutic use;
Treatment Outcome;
Urination Disorders/*drug therapy
- From:Journal of Korean Medical Science
2010;25(1):117-122
- CountryRepublic of Korea
- Language:English
-
Abstract:
We evaluated the therapeutic effects of tamsulosin for women with non-neurogenic voiding dysfunction. Women who had voiding dysfunctions for at least 3 months were included. Inclusion criteria were age > or =18 yr, International Prostate Symptom Score (IPSS) of > or =15, and maximum flow rate (Q(max)) of > or =12 mL/sec and/or postvoid residuals (PVR) of > or =150 mL. Patients with neurogenic voiding dysfunction or anatomical bladder outlet obstruction were excluded. All patients were classified according to the Blaivas-Groutz nomogram as having no or mild obstruction (group A) or moderate or severe obstruction (group B). After 8 weeks of treatment, treatment outcomes and adverse effects were evaluated. One hundred and six patients were evaluable (70 in group A, 36 in group B). After treatments, mean IPSS, bother scores, Q(max), PVR, diurnal and nocturnal micturition frequencies and scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire (BFLUTS-SF) were changed significantly. Eighty-nine patients (84%) reported that the treatment was beneficial. The proportion of patients reported that their bladder symptoms caused "moderate to many severe problems" were significantly decreased. No significant difference were observed between the groups in terms of IPSS, bother score, Q(max), PVR, micturition frequency, and BFLUTS-SF changes. Adverse effects related to medication were dizziness (n=3), de novo stress urinary incontinence (SUI) (n=3), aggravation of underlying SUI (n=1), fatigue (n=1). Tamsulosin was found to be effective in female patients with voiding dysfunction regardless of obstruction grade.
